Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
HKD 13.9
(17.0%)
HKD 13.9
(17.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 716.91 Million CNY | 34.28% |
| 2022 | 533.88 Million CNY | 50.58% |
| 2021 | 354.55 Million CNY | 39.84% |
| 2020 | 253.54 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 205.24 Million CNY | 0.0% |
| 2024 Q1 | 205.24 Million CNY | 5.24% |
| 2023 FY | 716.91 Million CNY | 34.28% |
| 2023 Q4 | 195.03 Million CNY | 0.0% |
| 2023 Q3 | 195.03 Million CNY | 19.35% |
| 2023 Q2 | 163.41 Million CNY | 0.0% |
| 2023 Q1 | 163.41 Million CNY | 7.25% |
| 2022 Q1 | 114.56 Million CNY | 2.52% |
| 2022 Q4 | 152.37 Million CNY | 0.0% |
| 2022 FY | 533.88 Million CNY | 50.58% |
| 2022 Q3 | 152.37 Million CNY | 33.0% |
| 2022 Q2 | 114.56 Million CNY | 0.0% |
| 2021 Q2 | 65.52 Million CNY | 0.0% |
| 2021 FY | 354.55 Million CNY | 39.84% |
| 2021 Q4 | 111.75 Million CNY | 0.0% |
| 2021 Q3 | 111.75 Million CNY | 70.54% |
| 2021 Q1 | 65.52 Million CNY | 0.0% |
| 2020 FY | 253.54 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 484.71 Million HKD | -47.903% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | 86.531% |